Cell Host & Microbe
Volume 27, Issue 6, 10 June 2020, Pages 992-1000.e3
Journal home page for Cell Host & Microbe

Clinical and Translational Report
Complex Immune Dysregulation in COVID-19 Patients with Severe Respiratory Failure

https://doi.org/10.1016/j.chom.2020.04.009Get rights and content
open access

Highlights

  • Severe COVID-19 patients display immune dysregulation or macrophage activation syndrome

  • Severe respiratory failure is associated with a major decrease of HLA-DR on CD14 monocytes

  • CD4 cell and NK cell cytopenias are characteristics of severe COVID-19

  • IL-6 blocker Tocilizumab partially rescues SARS-CoV-2-associated immune dysregulation

Summary

Proper management of COVID-19 mandates better understanding of disease pathogenesis. The sudden clinical deterioration 7–8 days after initial symptom onset suggests that severe respiratory failure (SRF) in COVID-19 is driven by a unique pattern of immune dysfunction. We studied immune responses of 54 COVID-19 patients, 28 of whom had SRF. All patients with SRF displayed either macrophage activation syndrome (MAS) or very low human leukocyte antigen D related (HLA-DR) expression accompanied by profound depletion of CD4 lymphocytes, CD19 lymphocytes, and natural killer (NK) cells. Tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6) production by circulating monocytes was sustained, a pattern distinct from bacterial sepsis or influenza. SARS-CoV-2 patient plasma inhibited HLA-DR expression, and this was partially restored by the IL-6 blocker Tocilizumab; off-label Tocilizumab treatment of patients was accompanied by increase in circulating lymphocytes. Thus, the unique pattern of immune dysregulation in severe COVID-19 is characterized by IL-6-mediated low HLA-DR expression and lymphopenia, associated with sustained cytokine production and hyper-inflammation.

Keywords

dysregulation
interleukin-6
monocytes
lymphopenia
HLA-DR
ferritin
macrophage activation
SARS-CoV-2
COVID-19
respiratory failure

Cited by (0)

10

Lead Contact